New tools for medication review: DRP in patients treatment with proton pump inhibitors
To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022. Descriptive and retrospective observational study. The pharmacotherapeutic history...
Gespeichert in:
| Veröffentlicht in: | Atención primaria 2024-05, Vol.56 (5), p.102836 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 102836 |
| container_title | Atención primaria |
| container_volume | 56 |
| creator | Gutiérrez-Igual, Salvador Lucas-Domínguez, Rut Martí Rodrigo, Alberto Romero Crespo, Isabel Montesinos Mezquita, M Carmen |
| description | To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.
Descriptive and retrospective observational study.
The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments. |
| doi_str_mv | 10.1016/j.aprim.2023.102836 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2907196990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2907196990</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-4c76e2f2844dc364e59270759e46f22c321745c4991b640dbc088a843208c1333</originalsourceid><addsrcrecordid>eNpNkF9LwzAUxYMobk4_gSB59KUzuUmbxDeZf2GoiPpa2ixlGW1Tk9ThtzfiBJ_O4fDjcs9B6JSSOSW0uNjMq8Hbbg4EWEpAsmIPTWkuZEZB5Pv__AQdhbAhBEAxcYgmTNKcyJxM0fuj2eLoXBtw4zzuzMrqKlrXY28-rdle4uuXZ2x7PKTU9DHg6E0Vu2Tx1sY1HryLiR7GbkjY2tY2Oh-O0UFTtcGc7HSG3m5vXhf32fLp7mFxtcwGoDRmXIvCQAOS85VmBTe5AkFErgwvGgDNgAqea64UrQtOVrUmUlaSMyBSU8bYDJ3_3k1vfIwmxLKzQZu2rXrjxlCCIoKqQimS0LMdOtapZvmzXeW_yr8t2DdYEmFr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2907196990</pqid></control><display><type>article</type><title>New tools for medication review: DRP in patients treatment with proton pump inhibitors</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Gutiérrez-Igual, Salvador ; Lucas-Domínguez, Rut ; Martí Rodrigo, Alberto ; Romero Crespo, Isabel ; Montesinos Mezquita, M Carmen</creator><creatorcontrib>Gutiérrez-Igual, Salvador ; Lucas-Domínguez, Rut ; Martí Rodrigo, Alberto ; Romero Crespo, Isabel ; Montesinos Mezquita, M Carmen</creatorcontrib><description>To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.
Descriptive and retrospective observational study.
The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.</description><identifier>ISSN: 1578-1275</identifier><identifier>EISSN: 1578-1275</identifier><identifier>DOI: 10.1016/j.aprim.2023.102836</identifier><identifier>PMID: 38150850</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>Aged ; Aged, 80 and over ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Female ; Humans ; Male ; Middle Aged ; Proton Pump Inhibitors - therapeutic use ; Retrospective Studies</subject><ispartof>Atención primaria, 2024-05, Vol.56 (5), p.102836</ispartof><rights>Copyright © 2023 The Authors. Publicado por Elsevier España S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38150850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gutiérrez-Igual, Salvador</creatorcontrib><creatorcontrib>Lucas-Domínguez, Rut</creatorcontrib><creatorcontrib>Martí Rodrigo, Alberto</creatorcontrib><creatorcontrib>Romero Crespo, Isabel</creatorcontrib><creatorcontrib>Montesinos Mezquita, M Carmen</creatorcontrib><title>New tools for medication review: DRP in patients treatment with proton pump inhibitors</title><title>Atención primaria</title><addtitle>Aten Primaria</addtitle><description>To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.
Descriptive and retrospective observational study.
The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Retrospective Studies</subject><issn>1578-1275</issn><issn>1578-1275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkF9LwzAUxYMobk4_gSB59KUzuUmbxDeZf2GoiPpa2ixlGW1Tk9ThtzfiBJ_O4fDjcs9B6JSSOSW0uNjMq8Hbbg4EWEpAsmIPTWkuZEZB5Pv__AQdhbAhBEAxcYgmTNKcyJxM0fuj2eLoXBtw4zzuzMrqKlrXY28-rdle4uuXZ2x7PKTU9DHg6E0Vu2Tx1sY1HryLiR7GbkjY2tY2Oh-O0UFTtcGc7HSG3m5vXhf32fLp7mFxtcwGoDRmXIvCQAOS85VmBTe5AkFErgwvGgDNgAqea64UrQtOVrUmUlaSMyBSU8bYDJ3_3k1vfIwmxLKzQZu2rXrjxlCCIoKqQimS0LMdOtapZvmzXeW_yr8t2DdYEmFr</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Gutiérrez-Igual, Salvador</creator><creator>Lucas-Domínguez, Rut</creator><creator>Martí Rodrigo, Alberto</creator><creator>Romero Crespo, Isabel</creator><creator>Montesinos Mezquita, M Carmen</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202405</creationdate><title>New tools for medication review: DRP in patients treatment with proton pump inhibitors</title><author>Gutiérrez-Igual, Salvador ; Lucas-Domínguez, Rut ; Martí Rodrigo, Alberto ; Romero Crespo, Isabel ; Montesinos Mezquita, M Carmen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-4c76e2f2844dc364e59270759e46f22c321745c4991b640dbc088a843208c1333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gutiérrez-Igual, Salvador</creatorcontrib><creatorcontrib>Lucas-Domínguez, Rut</creatorcontrib><creatorcontrib>Martí Rodrigo, Alberto</creatorcontrib><creatorcontrib>Romero Crespo, Isabel</creatorcontrib><creatorcontrib>Montesinos Mezquita, M Carmen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Atención primaria</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gutiérrez-Igual, Salvador</au><au>Lucas-Domínguez, Rut</au><au>Martí Rodrigo, Alberto</au><au>Romero Crespo, Isabel</au><au>Montesinos Mezquita, M Carmen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New tools for medication review: DRP in patients treatment with proton pump inhibitors</atitle><jtitle>Atención primaria</jtitle><addtitle>Aten Primaria</addtitle><date>2024-05</date><risdate>2024</risdate><volume>56</volume><issue>5</issue><spage>102836</spage><pages>102836-</pages><issn>1578-1275</issn><eissn>1578-1275</eissn><abstract>To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.
Descriptive and retrospective observational study.
The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).
The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.
The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.</abstract><cop>Spain</cop><pmid>38150850</pmid><doi>10.1016/j.aprim.2023.102836</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1578-1275 |
| ispartof | Atención primaria, 2024-05, Vol.56 (5), p.102836 |
| issn | 1578-1275 1578-1275 |
| language | eng ; spa |
| recordid | cdi_proquest_miscellaneous_2907196990 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Aged Aged, 80 and over Drug-Related Side Effects and Adverse Reactions - epidemiology Female Humans Male Middle Aged Proton Pump Inhibitors - therapeutic use Retrospective Studies |
| title | New tools for medication review: DRP in patients treatment with proton pump inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A13%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20tools%20for%20medication%20review:%20DRP%20in%20patients%20treatment%20with%20proton%20pump%20inhibitors&rft.jtitle=Atenci%C3%B3n%20primaria&rft.au=Guti%C3%A9rrez-Igual,%20Salvador&rft.date=2024-05&rft.volume=56&rft.issue=5&rft.spage=102836&rft.pages=102836-&rft.issn=1578-1275&rft.eissn=1578-1275&rft_id=info:doi/10.1016/j.aprim.2023.102836&rft_dat=%3Cproquest_pubme%3E2907196990%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2907196990&rft_id=info:pmid/38150850&rfr_iscdi=true |